The mechanism of action, Phase 3 MRCT results and post-market cases of the DFU new drug, Fespixon have been accepted for an oral presentation at WUWHS 2022
· Issued by Oneness Biotech Co., Ltd.
Close
Today's Information
Provided by: ONENESS BIOTECH CO., LTD.
SEQ_NO
1
Date of announcement
2022/03/01
Time of announcement
18:42:36
Subject
The mechanism of action, Phase 3 MRCT results and
post-market cases of the DFU new drug, Fespixon have
been accepted for an oral presentation at WUWHS 2022
Date of events
2022/03/02
To which item it meets
paragraph 12
Statement
1.Date of institutional investor conference:2022/03/02
2.Time of institutional investor conference:20:00 (TPE time)
3.Location of institutional investor conference:online
4.Outline of institutional investor conference:
(1)The mechanism of action, Phase 3 MRCT results and post-market cases of
Fespixon (new drug for diabetic foot ulcers) have been accepted for an
oral presentation at WUWHS (World Union of Wound Healing Societies) 2022
on 2nd of March, 2022 (GST 4:00 -6:00 PM). The WUWHS Congress this year
will be held as a hybrid conference with virtual and on-site
participation due to the global pandemic of COVID-19.
(2)The World Union of Wound Healing Societies (WUWHS) is the premier wound
care professional association which presents more than 90% of all
practicing wound care specialists and important wound care associations
in the world. The main purpose of WUWHS is to enhance the practice,
education, study and global cooperation in wound healing to deliver the
best treatment and care to the patients with acute and chronic wounds.
The WUWHS is held every 4 years attended by more than 4,000 wound care
specialists.
5.Any other matters that need to be specified:
The presentation slides will be made publicly by being uploaded to Market
Observation Post System according to the regulation.
